Kalmente (Mometasone Furoate Anhydrous)

Mometasone furoate binds to glucocorticoid receptors in the cells lining the nasal passages. This binding modifies gene expression, decreasing the production of inflammatory mediators and reducing swelling, mucus formation and immune cell infiltration, which alleviates nasal allergy symptoms.

The appropriate dose of Kalmente is set by the prescribing healthcare professional based on the patient’s age, severity of symptoms and clinical response. Dosage instructions are individualized and should be followed exactly as written on the prescription label.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before starting Kalmente.

To order Kalmente, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kalmente (mometasone furoate) is a high‑potency intranasal corticosteroid with a favorable safety profile when used as directed. Compared with lower‑potency options such as fluticasone, it may achieve symptom control with fewer daily sprays, but choice of therapy should be guided by the clinician’s assessment of efficacy, tolerability and patient preference.

Kalmente should be stored at room temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from moisture and direct sunlight, and keep it out of reach of children.

Kalmente is administered as a nasal spray. The patient gently shakes the bottle, primes it if required, tilts the head slightly forward, inserts the nozzle into one nostril, and sprays the prescribed number of sprays while breathing in gently. The process is then repeated in the other nostril if instructed.

Serious but rare risks include nasal septal perforation, severe allergic reactions such as anaphylaxis, and possible systemic effects like adrenal suppression with prolonged high‑dose use. Any signs of unusual bleeding, persistent nose pain, visual changes or systemic symptoms should prompt immediate medical evaluation.

Kalmente should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation, in patients with active untreated nasal infections, and in those for whom the prescriber determines that the risks outweigh the benefits, such as certain immunocompromised patients.